Lataa...

Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone

The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical landscape of prostate cancer treatment. Both drugs were designed to further suppress androgen receptor (AR) signaling, which is restored following first-line androgen deprivation therapies. Resistance to enzalutamide...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Nakazawa, Mary, Antonarakis, Emmanuel S., Luo, Jun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2014
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4167475/
https://ncbi.nlm.nih.gov/pubmed/25048254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12672-014-0190-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!